Cardiopathy hypertensive heart disease: from mild diastolic dysfunction to depressed systolic function. Systematic review with meta-analysis

Authors

Keywords:

Hypertensive heart disease, Prognostic factors, Systematic review, Meta-analysis.

Abstract

Introduction: hypertensive heart disease stands out among the target organ lesions caused by arterial hypertension, due to its high morbidity and disability.

Objective: to evaluate the prognostic capacity of the different factors associated with the evolutionary changes of hypertensive heart disease up to depressed systolic function.

Method: a systematic review with meta-analysis of case-control, cohort and meta-analysis studies was carried out. For which an electronic literature search was performed for the various studies related to the subject from April 10 to May 24, 2024.

Results: it was demonstrated in the meta-analysis that the factors with the greatest association with the evolutionary changes of hypertensive heart disease were: the presence of microalbuminuria (HR: 3.978; 95 % CI: 2.131-7.428), C-reactive protein (HR: 2.141; 95 % CI: 1.247-3.675) and the effects of arterial hypertension (HR: 2.105; 95 % CI: 1.647-2.692). The models for assessing cardiovascular risk did not show useful calibration and discrimination for predicting changes in the evolution of hypertensive heart disease.

Conclusions: a significant association was demonstrated between the different prognostic factors and the evolutionary changes of hypertensive heart disease. The need for a new prognostic tool based on these factors is evident in order to improve the accuracy and precision of risk assessment.

Downloads

Download data is not yet available.

Author Biographies

Liannys Lidia Naranjo Flores, Hospital General Provincial Carlos Manuel de Céspedes, Bayamo, Granma

Especialista de segundo grado en Medicina Interna. Profesor Asistente.

Alexis Álvarez Aliaga, Hospital General Provincial Carlos Manuel de Céspedes, Bayamo, Granma

Doctor en Ciencias Médicas. Especialista de segundo grado en Medicina Interna. Profesor e Investigador Titular

Julio César González Aguilera, Hospital General Provincial Carlos Manuel de Céspedes, Bayamo, Granma

Doctor en Ciencias Médicas. Especialista de segundo grado en Medicina Interna y Medicina Intensiva y Emergencias. Profesor e Investigador Titular

Alexis Suárez Quesada, Hospital General Provincial Carlos Manuel de Céspedes, Bayamo, Granma

Doctor en Ciencias Médicas. Especialista de segundo grado en Medicina Interna. Profesor Titular

Andrés José Quesada Vázquez, Hospital General Provincial Carlos Manuel de Céspedes, Bayamo, Granma

Doctor en Ciencias Médicas. Especialista de segundo grado en Medicina Interna. Profesor Titular

References

1. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45(38):3912-4018.

2. Nwabuo CC, Vasan RS. Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy. Curr Hypertens Rep. 2020;22(2):11.

3. Álvarez-Aliaga A, Quesada-Vázquez AJ, Suárez-Quesada A, de Llano Sosa D. Design and validation of an Index to predict the development of Hypertensive Cardiopathy. J Cardiol Cardiovasc Med. 2018; 3:008-022.

4. Bauersachs J, Soltani S. Herzinsuffizienz: Leitlinien-Update der ESC 2023 [Heart failure: update of the ESC 2023 guidelines]. Herz. 2024; 49(1):19-21.

5. Dai H, Bragazzi NL, Younis A, Zhong W, Liu X, Wu J, et al. Worldwide Trends in Prevalence, Mortality, and Disability-Adjusted Life Years for Hypertensive Heart Disease From 1990 to 2017. Hypertension. 2021; 77(4):1223-33.

6. Yelenski S, Zayat R, Spillner J, Donuru SR, Kolashov A, Khattab MA, et al. Apical Sparing of Longitudinal Strain as a Specific Pattern of Myocardial Fibrosis in Patients with Severe Left Ventricular Hypertrophy: A Comparison between Deformation Imaging and Histological Findings. J Clin Med. 2024; 13(20):6141.

7. Wang Z, Zhu Z, Shen J, Zhang Y, Wang T, Xu Y, et al. Predictive value of remnant cholesterol for left ventricular hypertrophy and prognosis in hypertensive patients with heart failure: a prospective study. Lipids Health Dis. 2024; 23(1):294.

8. Patel RB, Colangelo LA, Reis JP, Lima JAC, Shah SJ, Lloyd-Jones DM. Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later Life: Coronary Artery Risk Development in Young Adults (CARDIA) Study. JAMA Cardiol. 2020;5(2):184-92.

9. Álvarez-Aliaga A, Frómeta-Guerra A, Suárez-Quesada A, del Llano-Sosa D, Berdú-Saumell J, Lago-Santiesteban YA. Prognostic model of the adaptive changes from hypertensive cardiopathy: from mild diastolic dysfunction to depressed systolic function. Medwave. 2020; 20(3):e7873.

10. Gu Q, Dillon CF, Burt VL, Gillum RF. Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens. 2010 Jan; 23(1):38-45.

11. Kaczmarski KR, Sozio SM, Chen J, Sang Y, Shafi T. Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES). BMC Nephrol. 2019;20(1):138.

12. Hao G, Wang X, Chen Z, Zhang L, Zhang Y, Wei B, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015. Eur J Heart Fail. 2019; 21(11):1329-37.

13. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996; 275(20):1557-62.

14. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure–meta-analyses of randomized trials. J Hypertension. 2016; 34(3):373-84.

15. Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, et al. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc. 2017; 6(7):e005156.

16. Tovillas-Morán FJ, Zabaleta-del-Olmo E, Dalfó-Baqué A, Vilaplana Cosculluela M, Galcerán JM, Coca A. Morbimortalidad cardiovascular y patrones geométricos del ventrículo izquierdo en pacientes hipertensos atendidos en atención primaria. Rev Esp Cardiol. 2009; 62:246-54.

17. Aune D, Schlesinger S, Neuenschwander M, Feng T, Janszky I, Norat T, et al. Diabetes mellitus, blood glucose and the risk of heart failure: A systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2018; 28(11):1081-91.

18. Nielsen TL, Plesner LL, Warming PE, Mortensen OH, Iversen KK, Heaf JG. FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction. Nefrologia (Engl Ed). 2019; 39(3):258-68.

19. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population: Management of comorbidities in kidney disease in the 21st century: Anemia and bone disease. Kidney International. 2003; 64(87): S24-S31.

20. Liu M, Liang Y, Zhu J, Yang Y, Ma W, Zhang G. Albumin-to-creatinine ratio as a predictor of all-cause mortality and hospitalization of congestive heart failure in Chinese elder hypertensive patients with high cardiovascular risks. Clin Hypertens. 2018; 24:12.

21. Okin PM, Wachtell K, Devereux RB, Nieminen MS, Oikarinen L, Viitasalo M, et al. Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. Am J Hypertens. 2008; 21(3):273-9.

22. Bailey LN, Levitan EB, Judd SE, Sterling MR, Goyal P, Cushman M, et al. Association of Urine Albumin Excretion With Incident Heart Failure Hospitalization in Community-Dwelling Adults. JACC Heart Fail. 2019 ;7(5):394-401.

23. Maio R, Perticone M, Suraci E, Sciacqua A, Sesti G, Perticone F. Endothelial dysfunction and C‐reactive protein predict the incidence of heart failure in hypertensive patients. ESC Heart Failure. 2021; 8(1): 399-407.

24. Chivite D, Franco J, Formiga F, Salamanca-Bautista P, Manzano L, Conde-Martel A, et al. Valor pronóstico a corto plazo de la proteína C reactiva en ancianos con insuficiencia cardíaca aguda. Rev Cli Española. 2019; 219(1):10-7.

25. Lakhani I, Wong MV, Hung JKF, Gong M, Waleed KB, Xia Y, et al. Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart Fail Rev. 2021 ;26(5):1141-50.

26. Jackson CE, Castagno D, Maggioni AP, Køber L, Squire IB, Swedberg K, et al. Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. Eur Heart J. 2015;36(18):1106-14.

27. Mancusi C, Losi MA, Izzo R, Canciello G, Carlino MV, Albano G, et al. Higher pulse pressure and risk for cardiovascular events in patients with essential hypertension: The Campania Salute Network. Eur J Prev Cardiol. 2018; 25(3):235-43.

28. Qiu W, Xiao X, Cai A, Gao Z, Li L. Pulse pressure and all-cause mortality in ischaemic heart failure patients: a prospective cohort study. Ann Med. 2022 Dec;54(1):2701-9.

29. Haider AW, Larson MG, Franklin SS, Levy D; Framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2003; 138(1):10-6.

30. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017; 357j2099.

31. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007; 335(7611):136.

32. Al-Shamsi S. Performance of the Framingham coronary heart disease risk score for predicting 10-year cardiac risk in adult United Arab Emirates nationals without diabetes: a retrospective cohort study. BMC Fam Pract. 2020;21(1):175.

33. Liu AB, Lin YX, Meng TT, Tian P, Chen JL, Zhang XH, et al. Global prevalence and disability-adjusted life years of hypertensive heart disease: A trend analysis from the Global Burden of Disease Study 2019. J Glob Health. 2024;14: 04172.

34. Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023; 329(10):827-38.

35. Zhou B, Li C, Shou J, Zhang Y, Wen C, Zeng C. The cumulative blood pressure load and target organ damage in patients with essential hypertension. J Clin Hypertens (Greenwich). 2020; 22(6):981-90.

36. Oliveros E, Patel H, Kyung S, Fugar S, Goldberg A, Madan N, Williams KA. Hypertension in older adults: Assessment, management, and challenges. Clin Cardiol. 2020; 43(2):99-107.

37. Díez J, Butler J. Growing Heart Failure Burden of Hypertensive Heart Disease: A Call to Action. Hypertension. 2023;80(1):13-21.

38. Kumric M, Ticinovic Kurir T, Borovac JA, Bozic J. Role of novel biomarkers in diabetic cardiomyopathy. World J Diabetes. 2021;12(6):685-705.

39. Law JP, Pickup L, Pavlovic D. TownendJN, FerroetCJ. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations. J Hum Hypertens. 2023; 37:1-19. 40.

40. Llàcer P, Cobo Marcos M, de la Espriella R, Gayán Ordás J, Zegri I, Fort A, et al. Congestion as a crucial factor determining albuminuria in patients with cardiorenal disease. Clin Kidney J. 2024; 17(6):sfae140.

41. Kim BS, Yu MY, Park JK, Shin J, Shin JH. Association of Dipstick Proteinuria with Long-Term Mortality among Patients with Hypertensive Crisis in the Emergency Department. J Pers Med. 2022; 12(6):971.

42. Arvunescu AM, Ionescu RF, Cretoiu SM, Dumitrescu SI, Zaharia O, Nanea IT. Inflammation in Heart Failure-Future Perspectives. J Clin Med. 2023;12(24):7738.

43. Lakhani I, Wong MV, Hung JKF, Gong M, Waleed KB, Xia Y, et al. Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart Fail Rev. 2021; 26(5):1141-50.

44. Boncler M, Wu Y, Watala C. The Multiple Faces of C-Reactive Protein-Physiological and Pathophysiological Implications in Cardiovascular Disease. Molecules. 2019; 24(11):2062.

45. Qiu W, Xiao X, Cai A, Gao Z, Li L. Pulse pressure and all-cause mortality in ischaemic heart failure patients: a prospective cohort study. Ann Med. 2022 ;54(1):2701-9.

46. Ovchinnikov A, Potekhina A, Arefieva T, Filatova A, Ageev F, Belyavskiy E. Use of Statins in Heart Failure with Preserved Ejection Fraction: Current Evidence and Perspectives. Int J Mol Sci. 2024;25(9):4958.

Downloads

Published

2025-01-10

How to Cite

1.
Naranjo Flores LL, Aliaga A Álvarez, González Aguilera JC, Quesada AS, Quesada Vázquez AJ. Cardiopathy hypertensive heart disease: from mild diastolic dysfunction to depressed systolic function. Systematic review with meta-analysis. RM [Internet]. 2025 Jan. 10 [cited 2025 Jun. 28];29:e3098. Available from: https://revmultimed.sld.cu/index.php/mtm/article/view/3098

Issue

Vol. 29 (2025): Publicación Continua

Section

REVISIÓN SISTEMÁTICA

License

Avisos de derechos de autor propuestos por Creative Commons

1. Política propuesta para revistas que ofrecen acceso abierto

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).